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Background: Differences in quality-of-life outcomes after different surgical 
breast cancer treatment options, including breast reconstruction, are relevant 
for counseling individual patients in clinical decision-making, and for (soci-
etal) evaluations such as cost-effectiveness analyses. However, current litera-
ture shows contradictory results, because of use of different patient-reported 
outcome measures and study designs with limited patient numbers. The au-
thors set out to improve this evidence using patient-reported outcome mea-
sures in a large, cross-sectional study for different surgical breast cancer treat-
ment options.
Methods: Quality of life was assessed through the EQ-5D-5L, European 
Organization for Research and Treatment of Cancer Quality of Life Ques-
tionnaires C30 and BR23, and the BREAST-Q. Patients with different 
treatments were compared after propensity-weighted adjustment of pre-
treatment differences. The EQ-5D was used to value the effect of surgical 
complications.
Results: A total of 1871 breast cancer patients participated (breast-conserving 
surgery, n = 615; mastectomy, n = 507; autologous reconstruction, n = 330; 
and implant-based reconstruction, n = 419). Mastectomy patients reported 
the lowest EQ-5D score (mastectomy, 0.805, breast-conserving surgery, 0.844; 
autologous reconstruction, 0.849; and implant-based reconstruction, 0.850) 
and functioning scores of the C30 questionnaire. On the BREAST-Q, autolo-
gous reconstruction patients had higher mean Satisfaction with Outcome, 
Satisfaction with Breasts, and Sexual Well-being scores than implant-based 
reconstruction patients. Complications in autologous reconstruction patients 
resulted in a substantially lower quality of life than in implant-based recon-
struction patients.
Conclusions: This study shows the added value of breast conservation and 
reconstruction compared with mastectomy; however, differences among breast-
conserving surgery, implant-based reconstruction, and autologous breast re-
construction were subtle. Complications resulted in poorer health-related 
quality of life. (Plast. Reconstr. Surg. 146: 1, 2020.)
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Because 5-year survival rates for early-stage breast cancer are relatively high,1,2 the effects of breast cancer and its treatment 
on quality of life become more important, which 
may affect surgical decision-making. Because mas-
tectomy and breast-conserving surgery including 
radiotherapy have similar disease-free and over-
all survival,3–5 the effects of different treatment 
modalities on outcomes other than survival gain 
significance. Because loss of a breast may nega-
tively affect psychosocial health, body image, and 
sexual function,6 guidelines recommend that 
the possibility of breast reconstruction should be 
discussed with every patient scheduled for mas-
tectomy.7–9 Multiple options are available, either 
using autologous tissue (autologous breast recon-
struction) or breast implants (implant-based 
breast reconstruction), varying in costs, tim-
ing, duration, complication rates, and cosmetic 
results.6,10,11 Breast reconstruction aims to improve 
the patient’s well-being and health-related quality 
of life,6,10 but patients opting for breast reconstruc-
tion also have a risk of complications,12–15 recon-
struction failure,12,13 or disappointing (cosmetic) 
results.6 Consequently, shared decision-making 
between physicians and patients about the pre-
ferred surgical treatment is a complex tradeoff 
between outcomes and risks.
Health-related quality-of-life outcomes after 
different surgical breast cancer treatment options 
are relevant for counseling individual patients in 
clinical decision-making, and for societal evalua-
tions as cost-effectiveness analyses used in health 
policy. Research shows that posttreatment health-
related quality of life is relatively high in breast 
cancer patients, but evidence about (differences 
in) health-related quality of life after different 
treatment options is conflicting.16–19 This conflict-
ing evidence may be explained by variation in the 
use of patient-reported outcome measures, study 
designs, and patient populations. For instance, 
there are studies that both have and have not found 
differences in health-related quality of life between 
patients who had undergone breast-conserving sur-
gery or mastectomy.20 Also, several higher quality 
studies did not find statistically significant differ-
ences in health-related quality of life, body image, 
and sexuality between patients with or without 
breast reconstruction.21 We believe that evidence 
should be improved, as such information is rel-
evant for choosing a treatment in clinical decision-
making and for health policy. Until now, outcomes 
have been generally measured in small, cross-sec-
tional, single-center studies. Ideally, one would 
include all surgical options relevant to breast can-
cer patients in one large prospective cohort study.21 
Santosa et al. performed such a large prospective 
study, comparing patients with implant-based and 
autologous breast reconstruction.22 Furthermore, 
outcomes measured over a longer period would be 
of interest, as different surgical outcomes may have 
a different health-related quality-of-life course over 
time. For example, recovery from surgical compli-
cations will take additional time.
To improve the evidence on the impact of 
breast cancer surgery and consequently for clini-
cal decision-making and health policy, the present 
study aimed to compare health-related quality-of-
life outcomes for four common surgical breast 
cancer treatment options (i.e., breast-conserving 
surgery, mastectomy, autologous breast recon-
struction, and implant-based breast reconstruc-
tion). Health-related quality of life was assessed 
using multiple patient-reported outcome mea-
sures in a large, multicenter, retrospective, cross-
sectional cohort of breast cancer patients up to 
10 years after diagnosis. The second aim was to 
investigate the impact of complications on health-
related quality of life following these different 
surgical treatment options. We hypothesized that 
breast-conserving surgery and autologous breast 
reconstruction are favorable over implant-based 
breast reconstruction and mastectomy in terms 
of health-related quality of life, however, in the 
absence of complications, with mastectomy yield-
ing the least preferable outcomes.
PATIENTS AND METHODS
Study Population
Female breast cancer patients (n = 3804) from 
four hospitals in The Netherlands (one academic 
Related digital media are available in the full-text 
version of the article on www.PRSJournal.com.
A Video Discussion by Cristiane M. Ueno, M.D., 
accompanies this article. Go to PRSJournal.com 
and click on “Video Discussions” in the “Digital 
Media” tab to watch.
Disclosure: Prof. Dr. Busschbach is a member of 
the nonprofit EuroQoL Group and receives finan-
cial compensation for managerial activities for the 
group. For the remaining authors, no financial 
interests were declared. No funding was received for 
this work. 
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hospital and three general hospitals) were invited 
by mail to participate in a self-administered cross-
sectional online survey. Patients were included if 
they had been surgically treated for nonmetastatic 
breast cancer in the past 10 years (2008 to 2018). 
Patients who had developed distant metastases 
since curative treatment or who were not profi-
cient in Dutch were excluded. Four groups were 
formed based on the surgical procedure: breast-
conserving surgery, mastectomy, autologous breast 
reconstruction, and implant-based breast recon-
struction. Time between surgery and invitation was 
over 6 months, to ensure patients had recovered 
from the treatment. Patients who preferred com-
pleting a paper questionnaire were sent one on 
request. Respondents gave informed consent for 
processing their coded survey results. The Medi-
cal Ethics Committee of the Erasmus MC reviewed 
and approved the study protocol (MEC-2015-273).
Measures
The survey included questions regarding base-
line patient and treatment characteristics, includ-
ing surgical complications, and the following 
validated questionnaires.
EQ-5D-5L
This questionnaire of health status measures 
problems in five dimensions (mobility, self-care, 
usual activities, pain/discomfort, and anxiety/
depression), all with five levels of severity (no, 
slight, moderate, severe, and extreme prob-
lems). According to health state, a “value” can 
be assigned, where 0.00 and 1.00 represent the 
value for death and perfect health, respectively. 
This value is also referred to as utility, index score, 
or preference. The EQ-5D includes values of the 
general public in the valuation of health-related 
quality of life, resulting in “preference-weighted 
quality-of-life scores,” often referred to as “utili-
ties.” Utilities are used as outcomes in economic 
evaluations, which can inform health policy. A 
mean general population reference was obtained 
to compare study results to that of a sample of the 
Dutch general population.23
European Organization for Research 
and Treatment of Cancer Quality of Life 
Questionnaires C30 and BR23
The European Organization for Research 
and Treatment of Cancer (EORTC) Quality of 
Life Questionnaires measure health-related qual-
ity of life in cancer patients,24 and the breast can-
cer–specific Quality of Life Questionnaire BR23 
supplements the cancer-specific Quality of Life 
Questionnaire C30.25 Both consist of functioning 
and symptom scales; the C30 questionnaire also 
includes a global health status scale. All items and 
scales range from 0 to 100, with higher scores pre-
senting a higher level of functioning or general 
health for the functional and global health status 
scales, respectively, and higher scores represent-
ing a higher level of symptoms for the symptom 
scales.26
BREAST-Q
The BREAST-Q is treatment-specific patient-
reported outcome measure, developed to mea-
sure breast-related quality of life and satisfaction 
on several health-related quality-of-life domains. 
Six postoperative domains were used from the 
different modules, which were developed for 
the respective patient groups: Satisfaction with 
Breasts, Satisfaction with Outcome, Psychoso-
cial Well-being, Sexual Well-being, Physical Well-
being: Chest, and Physical Well-being: Abdomen. 
The raw scores of the BREAST-Q domains were 
converted to scores between 0 (worst) and 100 
(best) using the Q-Score software.27
Statistical Analysis
Twenty-five patients did not report their high-
est completed education level; these missing 
answers were imputed using a single imputation 
method. A propensity-score weighting for mul-
tiple treatments was calculated according to the 
method of McCaffrey et al.28 to adjust for covari-
ates that predict receiving any one of the four 
surgical treatment options, thereby reducing 
the effects of confounding. The following clini-
cal and sociodemographic characteristics were 
included in the propensity weight calculation: 
age at the time of survey, education, year of breast 
cancer diagnosis, year of surgery, chemotherapy, 
hormone therapy, and breast cancer recurrence. 
The EQ-5D Dutch general population reference 
sample was matched to all surgical groups using 
age and sex as the matching variables. Propensity 
weights were calculated by the Toolkit for Weight-
ing and Analysis of Nonequivalent Groups Pack-
age for Stata (StataCorp, College Station, Texas).29
For all responding patients, propensity-
adjusted patient and treatment characteristics and 
health-related quality of life were presented. Pro-
pensity weights were incorporated in the analyses 
using the Stata-SE14 survey (svy) postestimation 
function.30 Mean scores, confidence intervals, and 
pairwise comparisons were subsequently obtained 
and performed using the margins regression 
estimation function. Column proportions were 
chi-square tested. The utilities resulting from the 
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EQ-5D per surgical treatment were stratified by 
experienced surgical complications. Utilities per 
surgical treatment were plotted over the course of 
time in 3-year intervals (≤3; 3 ≤ 6; 6 ≤ 9; >9), start-
ing at the time of last breast reconstruction.
For statistical testing, two-sided values of 
p ≤ 0.05 were considered statistically significant. 
All analyses were performed in Stata-SE14.31
RESULTS
A total of 1871 of 3804 patients (49 percent) 
responded, consisting of 615 breast-conserving 
surgery, 507 mastectomy, 330 autologous breast 
reconstruction, and 419 implant-based breast 
reconstruction patients. Table 1 presents patient 
and treatment characteristics. Nearly all autolo-
gous breast reconstruction procedures were 
abdominally based free-flap reconstructions. After 
propensity-weighted adjustment, estimated group 
sizes were reduced to 434.0 breast-conserving sur-
gery, 386.3 mastectomy, 178.6 autologous breast 
reconstruction, and 295.5 implant-based breast 
reconstruction patients. Group sizes declined 
as patients with certain characteristics from one 
group occurred less frequently in another group, 
and thus received a relative score weight lower 
than 1. After propensity-weighted adjustment, bal-
ance was achieved for all variables, except for age 
and chemotherapy treatment.
Quality-of-Life Outcomes
Table 2 presents preference-based health-
related quality-of-life outcomes at the time of 
survey per group. Unadjusted results for the 
outcomes presented Table 2 can be found in 
Supplemental Digital Content 1. [See Table, 
Supplemental Digital Content 1, which shows the 
mean patient-reported quality-of-life scores of 
1871 breast cancer patients per surgical treatment 
and the Dutch general population, before (left) 
and after (right) propensity-weighted adjustment, 
http://links.lww.com/PRS/E97.] After propensity-
weighted adjustment, patients treated with mas-
tectomy reported a statistically significant lower 
mean EQ-5D score (0.805) compared to all other 
surgical groups (breast-conserving surgery, 0.844; 
autologous breast reconstruction, 0.849; implant-
based breast reconstruction, 0.850). Pairwise com-
parisons of the groups for the individual EQ-5D 
domains reflected these lower means for mastec-
tomy as well (Fig. 1).
Furthermore, for two EORTC Quality of Life 
Questionnaire C30 functioning scales, statistically 
significant differences were found. First, patients 
treated with implant-based breast reconstruction 
reported a statistically significant higher mean 
physical functioning (87.97) than patients with 
breast-conserving surgery (84.53) or mastectomy 
(82.94), although the value was comparable to 
that reported for autologous breast reconstruction 
(85.62). Second, implant-based breast reconstruc-
tion patients reported a statistically significant 
higher mean role functioning (86.02) compared 
to patients treated with mastectomy (80.70). 
Within the symptom scales, statistically signifi-
cant more favorable mean scores were found for 
breast-conserving surgery over mastectomy for 
pain (breast-conserving surgery, 15.41; mastec-
tomy, 18.93) and financial problems (breast-con-
serving surgery, 5.23; mastectomy, 8.22).
Based on the EORTC Quality of Life Ques-
tionnaire BR23 scores, mean body image was sig-
nificantly higher for breast-conserving surgery 
patients (breast-conserving surgery, 87.45; mas-
tectomy, 80.49; autologous breast reconstruction, 
82.28; implant-based breast reconstruction, 82.35). 
Breast-conserving surgery patients also reported 
the lowest mean arm symptoms (breast-conserv-
ing surgery, 12.68; mastectomy, 17.12; autolo-
gous breast reconstruction, 18.18; implant-based 
breast reconstruction, 16.82). In contrast, breast 
symptoms on average were more often reported 
by patients treated with breast-conserving surgery 
(13.45) than with mastectomy (9.94) or autolo-
gous breast reconstruction (8.79). Patients with 
autologous and implant-based breast reconstruc-
tion reported the highest mean sexual enjoyment 
(autologous breast reconstruction, 64.24; implant-
based breast reconstruction, 63.80) compared to 
breast-conserving surgery or mastectomy (breast-
conserving surgery, 57.03; mastectomy, 54.82).
For the BREAST-Q scales, patients with autolo-
gous breast reconstruction reported the highest 
mean Satisfaction with Breasts (autologous breast 
reconstruction, 71.29) compared to the other 
groups (breast-conserving surgery, 65.52; mastec-
tomy, 60.65; implant-based breast reconstruction, 
59.39). Interestingly, Satisfaction with Breasts for 
mastectomy and implant-based breast reconstruc-
tion did not differ significantly. Mean Satisfac-
tion with Outcomes and Satisfaction with Nipples 
scores were significantly higher in autologous than 
in implant-based breast reconstruction patients 
(autologous breast reconstruction, 75.75; implant-
based breast reconstruction, 66.37; and autologous 
breast reconstruction, 63.03; implant-based breast 
reconstruction, 54.96, respectively). Mastectomy 
patients reported the lowest mean Psychosocial 
Well-being (66.50) and Sexual Well-being (50.00).
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Effect of Complications on EQ-5D Outcomes
A total of 96 of 615 breast-conserving surgery 
patients (16 percent), 112 of 507 mastectomy 
patients (22 percent), 138 of 330 autologous breast 
reconstruction patients (42 percent), and 140 of 
419 implant-based breast reconstruction patients 
(33 percent) reported having experienced com-
plications following surgery (unadjusted groups). 
After propensity-weighted adjustment, patients 
treated with either breast-conserving surgery, mas-
tectomy, or autologous breast reconstruction who 
had experienced complications, showed statisti-
cally significant lower mean utilities than patients 
from the same groups who had not experienced 
complications (Table 3). Unadjusted results for 
the outcomes presented in Table 3 are shown in 
Supplemental Digital Content 2. [See Table, Sup-
plemental Digital Content 2, which shows the mean 
EQ-5D-5L utilities for 1871 breast cancer patients 
with or without surgical complications per treat-
ment group and the Dutch general population, 
before (left) and after (right) propensity-weighted 
adjustment, http://links.lww.com/PRS/E98.] How-
ever, mastectomy patients without complications 
(0.818) reported means similar to autologous 
breast reconstruction patients with complications 
(0.816) and implant-based breast reconstruction 
patients with complications (0.861). Mean EQ-5D 
scores of mastectomy patients who previously had 
undergone a breast reconstruction (e.g., failed 
breast reconstruction) and who never had under-
gone a breast reconstruction did not differ sig-
nificantly from each other (p = 0.943, results not 
shown).
For both breast reconstruction groups, prob-
lems reported according to the EQ-5D domain 
were stratified by complications (Fig. 2). Autolo-
gous breast reconstruction patients with compli-
cations reported problems for the usual activities 
and pain/discomfort domain statistically signifi-
cant more often than autologous breast recon-
struction patients without complications.
Figure 3 includes box plots presenting timelines 
of the utilities for autologous and implant-based 
breast reconstruction patients who had experienced 
complications, unadjusted by propensity weighting. 
In the first 3 years after a complicated breast recon-
struction, a relatively large proportion of autolo-
gous breast reconstruction patients experienced 
a severe impact on health-related quality of life. 
This negative impact on health-related quality of 
life recovered with time for both treatment modali-
ties. However, a larger proportion of implant-based 
breast reconstruction patients seemed to recover 
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up to the degree that they did not report prob-
lems on any of the EQ-5D dimensions within 6 to 
9 years after the last breast reconstruction surgery, 
compared to a much smaller portion of autologous 
breast reconstruction patients.
DISCUSSION
This study aimed to compare health-related 
quality-of-life outcomes for four common sur-
gical breast cancer treatment options (breast-
conserving surgery, mastectomy, autologous 
breast reconstruction, and implant-based breast 
reconstruction) to improve the evidence and 
consequently decision-making about breast can-
cer surgery. We found that mastectomy patients 
reported the lowest mean health-related quality of 
life (EQ-5D) and functioning (EORTC Quality of 
Life Questionnaire C30). Based on the BREAST-
Q, autologous breast reconstruction patients had 
statistically significant higher Satisfaction with 
Outcome and Satisfaction with Breasts and Sexual 
Well-being scores than implant-based breast recon-
struction patients. Patients with complications 
(except for implant-based breast reconstruction) 
reported statistically significant lower health-
related quality of life (EQ-5D) than patients with-
out complications; complications in autologous 
breast reconstruction patients resulted in a sub-
stantially lower health-related quality of life than 
in implant-based breast reconstruction patients.
The results show the added value of breast 
conservation and reconstruction compared to 
mastectomy; however, the differences between 
breast-conserving surgery, implant-based breast 
reconstruction, and autologous breast reconstruc-
tion were subtle. Indeed, we found many statisti-
cally significant differences, but given the high 
statistical power of our large study, most of them 
were small. Thus, on average, we found few clini-
cally relevant differences between breast-conserv-
ing surgery, implant-based breast reconstruction, 
Fig. 1. Propensity-weighted EQ-5D-5L subscale per surgical treatment and weighted Dutch general population. BCS, breast-con-
serving surgery; MAS, mastectomy without breast reconstruction; A-BR, mastectomy with autologous breast reconstruction; I-BR, 
mastectomy with implant breast reconstruction; GP, general population. Values in the same domain not sharing the same letter 
(a, b, and c) were significantly different at p < 0.05 using the adjusted Wald test.
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and autologous breast reconstruction for the vari-
ous health-related quality-of-life domains. How-
ever, the benefits of these subtle differences over 
a long time are a good reason to consider them in 
clinical decision-making, specifically when consid-
ering the effects of complications and the patient’s 
attitude toward the risks of complications.
Only one other study that reported utilities 
for surgically treated breast cancer patients receiv-
ing breast reconstruction was found (immediate 
implant-based breast reconstruction patients; 
mean score, 0.83).14 We found lower mean health-
related quality-of-life scores reported by mastec-
tomy patients and benefits in some health-related 
quality-of-life domains for breast-conserving 
surgery patients (higher body image and more 
favorable arm symptom) over all other surgi-
cally treated groups, which confirms previously 
reported results.15,20,32 The benefits of autologous 
compared to implant-based breast reconstruction 
(higher mean Satisfaction with Breasts/Satisfac-
tion with Outcome/Satisfaction with Nipples, and 
Table 3. Mean EQ-5D-5L Utilities for 1871 Breast Cancer Patients with or without Surgical Complications per 
Treatment Group and the Dutch General Population after Propensity-Weighted Adjustment*
BCS (95% CI) MAS (95% CI) A-BR (95% CI) I-BR (95% CI) GP (95% CI)
Group size, no. 434.0 386.3 178.6 295.5 N/A
No complications, % 82.3 75.0 53.4 68.4 100
  Mean EQ-5D-5L utilities 0.859a 
(0.844–0.875)
0.818b 
(0.796–0.840)
0.878a 
(0.854–0.902)
0.847ab 
(0.810–0.884)
0.833b 
(0.812–0.854)
Complications, % 17.7 25.0 46.6 31.6  
  Mean EQ-5D-5L utilities 0.771a 
(0.729–0.812)
0.771a 
(0.736–0.806)
0.816ab 
(0.780–0.853)
0.861b 
(0.834–0.888)
N/A
BCS, breast-conserving surgery; MAS, mastectomy without breast reconstruction; BR, breast reconstruction; A-BR, mastectomy with autologous 
BR; I-BR, mastectomy with implant BR; GP, general population; N/A, not applicable.
*Values in the same row and subtable not sharing the same superscript letters (a and b) were significantly different at p < 0.05 using the adjusted 
Wald test. Cells with no superscript letters were not included in the test. Tests assume equal variances.
Fig. 2. EQ-5D-5L subscale contrasting autologous breast reconstruction and implant-based breast reconstruction with or without 
surgical complication (unadjusted for propensity score). A-BR, mastectomy with autologous breast reconstruction; I-BR, mastec-
tomy with implant breast reconstruction; GP, general population; C, surgical complications; NC, no surgical complications. Values 
in the same domain not sharing the same letter (a, b, and c) were significantly different at p < 0.05 using the adjusted Wald test. 
Cells without letters (a, b, or c) were not included in the test. Tests assume equal variances.
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Sexual Well-being) were also reported by Santosa 
et al.22 However, in contrast, both the present 
study and Thorarinsson et al.33 did not find sta-
tistically significant differences between autolo-
gous and implant-based breast reconstruction on 
either the EQ-5D-5L or the EORTC Quality of 
Life Questionnaire outcomes. Thus, although the 
BREAST-Q results suggest that the patient’s per-
ception of their reconstructed breast(s) is favor-
able for autologous over implant-based breast 
reconstruction, this does not necessarily lead to 
better outcomes in terms of overall health-related 
quality of life.
The second aim was to assess the impact of 
complications after different surgical treatments. 
Indeed, if any clinically relevant differences were 
found,34 they seemed to be related to complica-
tions. Specifically for autologous breast recon-
struction, one should not ignore the impact of 
complications.35 Autologous breast reconstruction 
patients with complications (versus those without 
complications) had statistically significant lower 
mean utilities as measured with the EQ-5D, and 
more often had problems in the usual activities 
and pain/discomfort domains. Also, mean scores 
recovered faster for implant-based breast recon-
struction patients than for autologous breast 
reconstruction patients. Finally, a larger propor-
tion of autologous breast reconstruction patients 
never recovered up to the degree that they did not 
report problems on any of the EQ-5D dimensions.
The faster recovery after complications of 
implant-based breast reconstruction patients 
could explain why the utilities in patients with 
and without complications did not differ statisti-
cally. The symptoms and the longer lasting impact 
of complications in autologous breast recon-
struction patients may be inherent in the type of 
complications associated with these procedures. 
More specifically, failure of an implant-based 
breast reconstruction is often attributable to an 
infection, resulting in removal of the implant, 
later often followed by a new implant-based 
breast reconstruction. Total flap failure following 
autologous breast reconstruction requires a new 
and additional donor site, with its own donor-
site issues and complication risks. Women expe-
rience breast reconstruction (flap) failure as an 
emotionally very difficult life event,36 although 
previous studies have shown that physical and 
mental health after a breast reconstruction com-
plication generally recover to normal levels after 
a period.37,38
By measuring health-related quality of life 
using multiple, validated patient-reported out-
come measures in a large sample of patients fol-
lowing different types of breast cancer surgery, we 
were able to improve earlier, smaller, and less con-
sistent attempts to assess health-related quality of 
life in surgically treated breast cancer patients. Our 
statistically significant results confirm the findings 
of studies mentioned previously,15,20,22,32,35 thereby 
Fig. 3. EQ-5D-5L utilities over time in years (time between last breast reconstruc-
tion and questionnaire) for breast cancer patients following breast reconstruction 
with complications. A-BR, mastectomy with autologous breast reconstruction; 
I-BR, mastectomy with implant breast reconstruction.
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supporting the added value of breast conservation 
and reconstruction for breast cancer patients.
Furthermore, no predominant treatment 
option was found. This stresses the idea that all 
treatment options (that are physically feasible) 
should be considered for every patient. The ulti-
mate treatment decision should be predominantly 
based on the patient’s preferences, resulting in 
the alignment of the favorable assets (or domain 
scores) of each procedure and the patient’s goals 
and expectations with the expected final result 
of each procedure in addition to their attitudes 
toward complication risks. Although we have 
investigated decision-making in a previous study 
in a similar cohort of patients,39 it would have 
been interesting to have insight in the treatment 
rationale for the current patient cohort.
This study demonstrates the use of the unique 
assets of the EQ-5D, a “preference-based,” standard-
ized generic measure of health status that is suitable 
for a wide comparison of treatment options.40,41 A 
benefit of this preference-based health-related 
quality-of-life measure compared to commonly 
applied “non–preference-based” measures such as 
the EORTC instrument and the BREAST-Q is that 
its outcomes can be aggregated over time and, after 
multiplication with survival time, provides quality-
adjusted life-years.41 The EQ-5D utilities can be 
related to the period of each health state, and can 
therefore combine the “utility” of the advantages 
and disadvantages, such as complications of surgi-
cal procedures. Note that our data were not able 
to fully solve the question of how the utility of the 
benefits of a surgical procedure relates to the disu-
tility of complications, as this requires longitudinal 
data to represent the EQ-5D values and the time 
lived with or without a given complication. Never-
theless, the present data can still provide insights in 
the tradeoff between benefits and complications of 
the different surgical procedures.
Of further importance is that previous stud-
ies have not yet described utilities for the com-
plete range of breast cancer surgery options. 
This currently complicates the implementation 
of health economics and reimbursement deci-
sion-making. Clinical treatment value should be 
related to health care costs, which is the ultimate 
goal toward creating value-based health care.42 In 
our subsequent study, we will relate costs to the 
outcomes we found in the present study.
Some limitations are relevant in the interpre-
tation of our results. First, although propensity-
weighted adjustment was used to minimize the 
effects of bias caused by including patients from 
an observational cohort, one cannot exclude 
that relevant variables may still have influenced 
the results of our study.28 For instance, surgical 
treatment selection might be based on severity 
of comorbidities or performance status, which 
were both not available in our data. Nonresponse 
bias could have been induced by socioeconomic 
and procedure-related differences, as described 
by Berlin et al.43 Besides, surveys introduce a cer-
tain arbitrariness, as patients might understand or 
interpret questions or experiences in unintended 
ways.
CONCLUSIONS
We conclude that health-related quality of life 
of mastectomy patients was often the lowest, sup-
porting the added value of breast conservation 
and reconstruction in breast cancer patients. Fur-
thermore, we found that each surgical procedure 
has subtle favorable assets, with the most notable 
related to complications: a complication in autol-
ogous breast reconstruction patients resulted 
in a substantially lower health-related quality of 
life than in implant-based breast reconstruction 
patients, and mastectomy patients without compli-
cations had similar or lower mean EQ-5D scores 
compared to autologous or implant-based breast 
reconstruction patients with complications. This 
could support a discussion about the alignment 
of the patient’s goals, expectations, and attitudes 
toward complication risks with the expected final 
result of each procedure.
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